Plain-English translation of NCT07069647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a tool called VeriSee—artificial intelligence software that helps doctors detect two common eye diseases: diabetic retinopathy (damage to blood vessels in the eye caused by diabetes) and age-related macular degeneration (vision loss related to aging). Half of participants will receive AI-assisted screening that gives results immediately during their visit, while the other half will follow the standard approach of waiting for a follow-up appointment to discuss their results.
Many people with diabetes and older adults develop serious eye diseases but don't know it until the damage is advanced, because regular doctor's offices don't have specialized equipment to screen for these conditions. This trial is testing whether using AI software during routine visits can catch these diseases earlier and help more people get treatment before their vision is permanently affected.
You likely qualify if…
You likely don't qualify if…
You will have your eyes photographed using a standard camera in your doctor's office. Depending on which group you're randomly assigned to, you'll either receive your results immediately with explanation from your doctor (AI-assisted group) or be scheduled for a follow-up visit to discuss your results (standard care group). If any eye problems are detected in either group, you'll be referred to an eye specialist for further evaluation.
AI-generated summary from trial data · Aug 10, 2026 · Not medical advice
Taiwan